01 1Cambrex Corporation
01 1LORAZEPAM
01 1U.S.A
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2020-09-25
Pay. Date : 2020-09-21
DMF Number : 4517
Submission : 1982-05-04
Status : Active
Type : II
20
Cambrex Profarmaco Milano Srl, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for Cambrex is an innovative life sciences company with a refreshingly human approach.
One of their notable products is LORAZEPAM, with a corresponding US DMF Number 4517.
Remarkably, this DMF maintains an Active status since its submission on May 04, 1982, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of September 25, 2020, and payment made on September 21, 2020, indicating their dedication to facilitating drug approvals, Categorized as Type II
